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Background: Dyspnea may be a presenting symptom in progressive systemic sclerosis (SSc). Respiratory drive
(mouth occlusion pressure, MOP, at rest and during CO2 rebreathing, 7% CO2, 93% O2) is a major determinant of
dyspnea and may relate to the magnitude of dyspnea.
Methods: In a prospective design, MOP at 0.1 sec (P0.1) was measured in 73 SSc patients while breathing room air
and during CO2 rebreathing. An abnormal V’E/P0.1 is defined as < 8 L/min/cm H2O. Dyspnea scores were assessed
by a shortness of breath questionnaire (UCSD dyspnea scale).
Results: Mean P0.1 in patients with normal V’E/P0.1 (n = 45) was 1.1 ± 0.04 and 1.6 ± 0.08 cm H2O in patients with
abnormal V’E/P0.1 (n = 28), p <0.001. ΔP0.1/ΔPetCO2 differed significantly between these groups (0.45 versus
0.75 cm H2O/mmHg, P < 0.001), but no significant difference was present in ΔV’E/ΔPetCO2. V’E/P0.1 showed the
highest significant correlation with the UCSD dyspnea score (r = −0.76, p <0.001). UCSD cut-off value for abnormal
V’E/P0.1 was 8.5 (sensitivity 93%, specificity 96%, area under the curve 0.98).
Conclusions: In SSc patients an abnormal V’E/P0.1 better relates to the severity of dyspnea than traditional lung
function parameters and can easily be assessed at first outpatient consultation.
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Systemic sclerosis (SSc) is a rare, heterogeneous condition
of unknown etiology characterized by microvascular injury
and deposition of excess collagen in skin and internal
organs [1]. Principle subsets of SSc include limited
cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc)
[2]. Importantly, progressive systemic sclerosis may
involve interstitial lung disease (ILD) resulting into a
restrictive lung function pattern abnormality [1]. In
addition, pulmonary arterial hypertension (PAH) may
arise in the course of the disease [1]. Validated measures
to monitor progression of SSc are necessary for clinical
trials and routine care of patients with SSc. Dyspnea as a
presenting symptom occurs in 20% of all newly diagnosed
SSc patients and 70% of patients with SSc complicated by
ILD or PAH patients complain of dyspnea [1]. Import-
antly, early recognition of disease progression related
to organ damage and initation of treatment may improve* Correspondence: m.k.ninaber@lumc.nl
1Department of Pulmonology (C3), Leiden University Medical Center, PO Box
9600, Leiden 2300RC, the Netherlands
Full list of author information is available at the end of the article
© 2014 Ninaber et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhealth-related outcomes. Lung volumes and gas trans-
fer studies are related to disease severity in SSc [1] and
used for initation of treatment and evaluation. How-
ever, whether the magnitude of dyspnea relates to these
pulmonary function tests is not known.
The impedance of the respiratory system is influenced
by lung and chest wall compliance and respiratory flow
resistance [3]. An increased respiratory impedance is recog-
nized as the most frequent cause of dyspnea [3]. Other
respiratory abnormalities resulting into dyspnea may in-
clude hypoxia, respiratory muscle weakness or pulmonary
vasculopathy (pulmonary embolisms, pulmonary arterial
hypertension). In progressive SSc, dyspnea may arise from
an increased impedance of the respiratory system caused
by ILD. In SSc, ILD or limited chest wall excursions due
to a thickened thoracic skin is considered to cause this
increased impedance [4,5]. Furthermore, dyspnea may
result from an inappropriate ventilatory response upon
the chemoreflex drive at rest and to hypercapnia [6,7].
To assess the ventilatory output as an index of the re-
spiratory drive, resting ventilation (V’E) and tidal volumesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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output parameter of the respiratory drive since it is
affected by alterations in the impedance of the respira-
tory system (i.e. mechanical properties of the lung and
chest wall) independently of changes in respiratory
sensitivity to hypercapnia [3,6,9]. To assess the respiratory
drive, mouth occlusion pressures (MOP) as an index of
the output can be measured [3]. Important advantages
of this technique include the reproducibility within each
subject and reported values independent of age [10]. In a
study of normal subjects and patients with ILD, a V’E/P0.1
greater than 8 l/min/cm H2O sharply separated a normal
from an abnormal response [10]. Therefore, in patients
who report dyspnea and who have concomitant ILD, a low
V’E to a high P0.1 (i.e. low V’E/P0.1) is expected.
In addition to V’E/P0.1 at rest, the respiratory drive to
hypercapnia (P0.1 to CO2, i.e. ΔP0.1/ΔPetCO2) provides
insight into the central chemoreflex drive to hypercapnia
[11-13]. In patients with ILD and dyspnea, the central
chemoreflex drive may result into a falsely low ventilatory
response to hypercapnic stimulation [7]. To overcome
this, the central chemoreflex drive to hypercapnia may be
assessed by mouth occlusion pressures (ΔP0.1/ΔPetCO2)
[6,11,12].
Based on the above we hypothesized that in patients
with SSc the respiratory drive, as measured by P0.1, V’E/
P0.1 and mouth occlusion pressures to CO2 rebreathing,
may better relate to the magnitude of reported dyspnea
than the severity of gas transfer or lung volume impair-
ment as measured by PFTs. Furthermore, we hypo-
thesized that the respiratory drive to hypercapnia is
increased in SSc patients who reported dyspnea.Methods
Patients
We prospectively screened SSc patients referred to an
outpatient targeted health care program. All patients
underwent an intensive screening procedure which in-
cluded PFTs, serum laboratory testing, echocardiography,
high-resolution chest CT scanning (HRCT) and a cardio-
pulmonary exercise test (CPET). Furthermore, all patients
consulted a rheumatologist, cardiologist and a pulmo-
nologist. All tests were done in one or two consecutive
days. Patients were classified as limited systemic sclerosis
(lcSSc) or diffuse systemic sclerosis (dcSSc) according to
the LeRoy criteria [2].Ethics
The local Medical Ethical Committee of the Leiden Uni-
versity Medical Center approved the protocol. A written
informed consent was obtained from each patient prior
to enrollment.Standard pulmonary function testing
PFTs were measured in all SSc patients including spir-
ometry and gas transfer studies and expressed as per-
centage predicted [14,15]. Total lung capacity (TLC) was
measured by the multiple breath helium dilution method
[14] and diffusion capacity for carbon monoxide (DLCO)
by the single breath carbon monoxide method [15].
Measuring mouth occlusion pressures during resting
ventilation and CO2 rebreathing
Subjects were seated comfortably, attached to the mouth-
piece with a noseclip in place. At randomized intervals,
and without the subject’s knowledge, the inspiratory side
of the rebreathing circuit was occluded during late expir-
ation. The pressure generated at 0.1 s after the onset of
inspiration was obtained in each subject during several
minutes with a minimum of 10 measurements prior to the
rebreathing test [3]. Thereafter, occlusion pressures were
measured simultaneously during CO2 rebreathing at
randomized intervals [3,16]. The slope of this curve
was used as an index of the respiratory drive to hyper-
capnia (i.e. central chemoreflex drive) and reported
as ΔP0.1/ΔPetCO2 [3,16].
Measuring the hyperoxic ventilatory response to
hypercapnia (HCVR)
We used a simple rebreathing technique according to
Read’s rebreathing technique, which consisted of a re-
breathing bag filled with a gas mixture (7% CO2 and
93% O2) [17]. In the rebreathing bag, a total volume of
approximately twice the measured vital capacity of the
patient was used.
Under hyperoxia the ventilatory response to hypercap-
nia (HCVR) represents the central chemoreflex response
only, assuming that the peripheral chemoreflex drive is
suppressed by hyperoxia [16,17]. Equilibrium of pressures
between CO2 in cerebral blood and end-tidal PCO2 exhal-
ation at the mouth (PetCO2) is expected not to occur
before recirculation of cerebral blood flow [17]. Respiratory
volumes were recorded by a turbine volume measuring
device (Oxycon-Pro, Jaeger). The Oxycon Pro was cali-
brated according to the instruction manual before each
test (Oxycon instruction manual ver. 4.5. Erich Jaeger
GmbH, Hoechberg, Germany) [18]. Oxygen and CO2
analyzers were calibrated with room air and certified
calibration gases at 180 kPa (16% O2, 5% CO2 and 79%
N2). The flow turbine (Triple V, Erich Jaeger GmbH,
Hoechberg, Germany) was calibrated with a 3.00 liter
5530 series calibration syringe (Hans Rudolph, Inc,
Kansas City, USA). Both gas and volume calibration
were repeated until the difference between consecutive
calibrations was less than 1%. Therefore, measurements
were not considered to be influenced under hyperoxia.
Expired gas at the mouth was sampled continuously
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analyzer. The software calculated tidal volumes, inspira-
tory and expiratory times, minute ventilation, and PetCO2
on a breath-by-breath basis. The hyperoxic ventilatory
response to hypercapnia (HCVR) was measured during
several minutes after equilibrium between the end-tidal
CO2 and mixed venous CO2. In this phase, a linear increase
in V’E with respect to PetCO2 was observed. The slope of
this curve was used as the index of the ventilatory central
chemosensitivity and reported as ΔV’E/ΔPetCO2 [17].
UCSD shortness of breath questionnaire
We used a previously validated shortness of breath ques-
tionnaire which evaluates in 24-items self-reported short-
ness of breath while performing a variety of activities of
daily living [19]. It was administered by MKN prior to
the MOP and rebreathing study while the subject sitting
comfortably.
Statistical analysis
Statistical analysis was performed with the SPSS 20.0
package (SPSS, Inc., Chicago, IL, USA). Continuous vari-
ables are expressed as mean value ± standard deviations.
P values < 0.05 were considered significant. Categorical
data are presented as frequencies and percentages. Stat-
istical comparisons were performed by using Student’s
T-test for continuous variables, and chi square test for
binary variables. Correlations between clinical parame-
ters, pulmonary function tests, were expressed in terms
of Pearson’s or Spearman’s correlation coefficient when
appropriate. The receiver operating characteristic (ROC)
curve was used to evaluate the optimal cut-off value for the
UCSD dyspnea score in relation to an abnormal V’E/P0.1.
Results
In total, 73 SSc patients were prospectively evaluated
by measuring PFTs, MOP and the hyperoxic ventilatory
response to hypercapnia (HCVR). Patients were classified
by their V’E/P0.1 according to Scott GC and Burki NK
[10], where ≥ 8 l/min/cmH2O was defined as normal.
Anthropometric and lung function data are presented
in Table 1. In the group with a V’E/P0.1 ≥ 8 L/min/cmH20,
lcSSc patients were significantly more present. In all
patients with an abnormal V’E/P0.1 (< 8 L/min/cmH2O),
spirometric and gas transfer studies were significantly
lower. All SSc patients were normocapnic at rest
(PaCO2 = 5.24 ± 0.41 kPa).
Indices of MOP differed significantly between the two
groups (Table 2). In contrast, there was no difference
in the hyperoxic ventilatory response to hypercapnia.
In our study, patients with a normal V’E/P0.1 had a
mean ΔP0.1/ΔPetCO2 of 0.45 ± 0.19 cmH2O/mmHg,
which differed significantly from patients with an abnormal
V’E/P0.1. The latter group had an increased respiratorydrive to hypercapnia (mean ΔP0.1/ΔPetCO2 0.75 ± 0.42
cmH2O/mmHg).
All pulmonary function test parameters correlated
inversely and significantly with the UCSD shortness of
breath questionnaire (coefficient of correlation ranging
from −0.39 to −0.49). V’E/P0.1, however, showed the high-
est significant correlation with the UCSD dyspnea score
(r = −0.76, p < 0.001, Figure 1). The cut-off value in UCSD
dyspnea score for an abnormal V’E/P0.1 was 8.5 (sensitiv-
ity 93%, specificity 96%, area under the curve 0.98).
Discussion
We report that in SSc patients with an abnormal inspira-
tory respiratory drive (V’E/P0.1 < 8 L/min/cmH2O) the
sensation of dyspnea as measured by the UCSD dyspnea
score differed from SSc patients with a normal respira-
tory drive. In addition, with a cut-off value of 8.5, the
dyspnea score showed a high sensitivity and specificity
for an abnormal V’E/P0.1. Furthermore, an abnormal
V’E/P0.1 better relates to the magnitude of dyspnea than
traditional lung function parameters and in these SSc
patients an increased central chemoreflex drive to CO2
is present. Therefore, at first outpatient consultation,
SSc patients complaining of dyspnea can easily be classi-
fied by using mouth occlusion pressures.
We showed that the level of dyspnea perception mea-
sured by the UCSD shortness of breath questionnaire
[19] had a strong inverse correlation with the inspiratory
neuromuscular drive as measured by V’E/P0.1 (Figure 1).
A high dyspnea score and an increased respiratory drive
to hypercapnia suggest that the work of breathing is
increased due to an increased respiratory impedance [7,10].
An increased activation of central respiratory centers
results not only into an increase in minute ventilation
but also into an increased perception of dyspnea [20]. The
basis for this awareness originates from the exchange in
information between the motor and sensory cortex and is
referred to as corollary discharge [20]. Although the work
of breathing is not the sole cause of dyspnea, increased
effort as a result from an increased mechanical load
causes a heightened sense of respiratory effort. Conse-
quently, this may explain the strong correlation between
the dyspnea score and the respiratory drive in the present
study. This drive can be easily measured using mouth
occlusion pressures at rest. As our results indicate, it bet-
ter relates to dyspnea than impairment in lung volumes or
gas transfer and may be present before significant impair-
ment in these function tests arises. Therefore, measure-
ment of the neuromuscular inspiratory drive may function
in clinical practice in SSc patients complaining of dyspnea
as a screening tool for detection of ILD or PAH.
Ventilation and its components, tidal volume and breath-
ing frequency, depend on the compliance of the respira-
tory system and airway resistance [3,9-11]. Importantly,
Table 1 Anthropometric and pulmonary function data of 73 SSc patients classified by V’E/P0.1 ≥ 8 l/min/cmH2O [10]
V’E/P0.1 < 8 l/min/cmH2O N = 28 V’E/P0.1 ≥ 8 l/min/cmH2O N = 45 P value*
Age (yrs) 54.4 (11.8) 50.9 (14.4) 0.25
Female sex (%) 26 (93) 37 (82) 0.11
Height (cm) 164 (7.2) 171 (8.7) 0.002
Weight (kg) 67.1 (15.3) 69.8 (12.8) 0.43
BMI (cm/kg2) 24.8 (5.4) 23.9 (3.7) 0.48
lcSSc subtype (%) 10 (36) 34 (76) 0.02
PaO2 (kPa) 10.4 (0.36) 10.6 (0.29) 0.58
PaCO2 (kPa) 5.31 (0.41) 5.18 (0.43) 0.25
FVC (% pred) 92.1 (19.9) 111.1 (19.7) 0.001
DLCOc SB (% pred) 57.7 (15.8) 70.7 (15.1) 0.001
TLC-He (% pred) 81.5 (16.6) 95.4 (13.5) <0.001
FRC/TLC (%) 53 (17) 56 (7) 0.23
*P value expressed for student T-test.
PaO2 (partial arterial oxygen pressure, kPa).
PaCO2 (partial arterial carbon dioxide pressure, kPa).
FVC (forced vital capacity, % pred).
DLCOc SB (diffusion capacity for carbon monoxide single breath, % pred).
TLC-He (total lung capacity, helium-dilution, % pred).
FRC/TLC (ratio of functional residual capacity and TLC, %).
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breathe because of central or neuromuscular inadequacy
from those who cannot breathe because of mechanical
abnormalities of the chest. The ventilatory response to
hypercapnia is known for its large variability and reported
responses may vary from 2.0 to 4.7 L/min/mmHg [3,17].
Although a correction by FVC will lead to less variability
(reported values vary from 0.42 to 0.94 FVC/min/mmHg
[3]), measuring the respiratory drive in patients affected
by ILD using ventilatory parameters remains troublesome.
The mouth occlusion pressure generated by the inspira-
tory muscles at functional residual capacity (P0.1) has
been proposed as an useful test to avoid these disadvan-
tages [3,9-11]. It is independent of flow resistance and
respiratory compliance and less variability is observedTable 2 Indices of MOP, CO2 rebreathing and the UCSD dyspn
V’E/P0.1 < 8 l/min/cmH2O N = 28







*P value expressed for student T-test.
UCSD SOBQ (shortness of breath questionnaire; score range 0–120).
P0.1 (mouth occlusion pressure at 0.1 second; cmH2O).
V’E (minute ventilation; L/min).
V’E/P0.1 (central inspiratory neuromuscular respiratory drive; L/min/cmH2O).
ΔV’E/ΔPetCO2 (hyperoxic ventilatory response to hypercapnia; L/min/mmHg).
(ΔV’E/FVC)/ΔPetCO2 (hyperoxic ventilatory response to hypercapnia, corrected for FVC;
ΔP0.1/ΔPetCO2 (slope of occlusion pressure to hypercapnia; cmH2O/mmHg).in various subjects [3,10]. Taken this together, we argue
that ventilation and its components, may not represent an
accurate output of the respiratory drive in our patients.
In daily practice, measuring P0.1 is very simple to apply
and joined with a rebreathing bag, measurement of CO2
responsiveness is possible. In normal subjects, P0.1 values
of 0.75-1.5 cmH20 have been described [3,10]. In addition,
normal V’E/P0.1 is defined by ≥ 8 L/min/cmH2O, as
evaluated by Scott and Burki [10]. The responsiveness to
hypercapnia by measuring P0.1 (ΔP0.1/ΔPetCO2) in nor-
mal subjects is reported to be 0.17-0.49 cmH2O/mmHg
[3,16]. This is in agreement with our results of SSc patients
with a normal V’E/P0.1 (Table 2, mean ΔP0.1/ΔPetCO2
0.45 cmH2O/mmHg). Thus, in these SSc patients, the
respiratory compliance and airflow resistance did notea score [18] of 73 SSc patients









Figure 1 Correlation between the UCSD dyspnea score [18] and
V’E/P0.1 in 73 prospectively screened SSc patients. Vertical line
set at V’E/P0.1 = 8 L/min/cmH2O. Horizontal line set at UCSD 8.5.
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capnia and is therefore considered to be normal. Further-
more, our data of mouth occlusion pressures during resting
minute ventilation and during CO2 rebreathing in patients
with normal V’E/P0.1 are consistent with those of others
[3,7,10,21]. However, in the present study no significant
difference was seen in ΔV’E/ΔPetCO2 between the groups
as classified by V’E/P0.1 (Table 2). Since there was a sig-
nificant difference present between these groups using
mouth occlusion pressures, minute ventilation may not
represent the neuromuscular drive adequately in SSc
patients with an increased respiratory impedance.
Although our reported values of the respiratory drive, as
measured by P0.1, were approximately similar, differences
from those previously reported by Walterspacher et al. are
present [21]. Potential reasons may include the differences
in degree of restrictive lung function as measured by FVC
% predicted. Our SSc patients with an abnormal V’E/P0.1
had mildly reduced FVC% predicted and may have pre-
served inspiratory muscle function. Furthermore, our SSc
patients did not avoid activities provoking dyspnea result-
ing into deconditioning and muscle wasting. Secondly,
they did not use immunosuppressive agents affecting
respiratory muscle function (prednisone). Finally, poly-
neuropathy, which may cause an impaired respiratory
muscle function, was not likely in our patients. There-
fore, respiratory drive was considered to be appropriate
in our SSc population.
In our study, patients with a low V’E/P0.1 had an in-
creased responsiveness to hypercapnia which suggests an
increased central respiratory drive (Table 2). This group
was characterized by fewer limited SSc patients, a lower
forced vital capacity, more impaired gas transfer and a
lower lung volume (Table 1). Importantly, the majority of
these patients had evidence of interstitial lung disease on
their HRCT and some patients had an elevated tricuspidinsufficiency gradient (data not shown). The disease dur-
ation did not differ between these groups. The difference
in V’E/P0.1 between the groups are related to SSc disease
severity and therefore influence the impedance of the
respiratory system. Consequently, differences in V’E/P0.1
were observed.
Similar results are reported by Gorini and coworkers in
normocapnic ILD patients without SSc [7]. This contrasts
to the concept of gradual down-regulation in central
respiratory sensitivity for carbon dioxide in scleroderma
patients [4]. DiMarco and coworkers concluded that in
patients with ILD, non-chemical, and presumably neural,
mechanisms, both increase respiratory drive and alter the
breathing pattern [22].
Several factors may influence the central sensitivity to
CO2 as measured by the ventilatory response to hypercap-
nia, such as the hormonal status, sex, age, use of sedative
agents and caffeine [8,17]. However, these factors will
generally not result into an abnormal V’E/P0.1 since the
compliance of the respiratory system or airway resistance
is not affected.
Some considerations may apply to our study. First, we
evaluated MOP and CO2 rebreathing in patients with
systemic sclerosis. We used a dataset of normal values for
normal resting minute ventilation as a function of occlusion
pressures (V’E/P0.1) [10]. As reported by others a value
higher than 8 L/min/cmH2O, independent of age or sex,
identifies subjects with normal PFTs and therefore provides
a reliable index of respiratory drive [3,10]. Consequently,
we restricted our measurements in a patient group, only
classified by V’E/P0.1. Our study contained 73 patients,
which was similar to previous studies evaluating mouth
occlusion pressures [3,10], and considered to be sufficient
for group difference statistics. Despite the relatively mild
range in low dyspnea scores (range 0–21; Figure 1), a sig-
nificant difference in V’E/P0.1 and ΔP0.1/ΔPetCO2 was
present (Table 2), indicating the sensitivity of the mouth
occlusion pressure test. Furthermore, assessing V’E/P0.1
to an additional load such as exercise may have increased
this difference since airflow resistance will increase and
consequently the impedance of the respiratory system.
Secondly, we did not measure the sensation of dyspnea,
as assessed at rest by the UCSD questionnaire, during
CO2 rebreathing. To evaluate the relationship between the
intensity of dyspnea and respiratory chemosensitivity may
have strengthen our results, however this questionnaire
was not designed to be administered during a rebreathing
or exercise test.
Conclusions
In summary, the results of the present study show that
patients with systemic sclerosis display a substantial
variability in the ventilatory response to hypercapnia.
In contrast, mouth occlusion pressures, independent of
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accurate outcome parameter in combination with minute
ventilation as an initial evaluation for mild dyspnea. They
better relate to the magnitude of patient reported dyspnea
than traditional lung function parameters such as FVC or
DLCO% predicted. Furthermore, in our SSc patients with
an abnormal V’E/P0.1, an increased respiratory drive to
hypercapnia was present. Since dyspnea is one of the most
frequently reported symptoms at first consultation in SSc,
an easy test to discriminate between normal or abnormal
respiratory mechanics would be obligatory. Therefore, we
suggest that an abnormal V’E/P0.1 in combination with
reported dyspnea indicates further assessment of respira-
tory involvement in SSc patients.
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